|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang J, Shen L, Yang Q and Zhang C:
Overexpression of metadherin mediates metastasis of osteosarcoma by
regulating epithelial-mesenchymal transition. Cell Prolif.
47:427–434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Konings AW, Hettinga JV and Kampinga HH:
Osteosarcoma in adolescents and young adults: New developments and
controversies. Thermal chemosensitization of cDDP-resistant cells.
Cancer Treat Res. 62:93–100. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi
X and Hoang BH: The Wnt signaling pathway: Implications for therapy
in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu CL, Tsai HC, Chen ZW, Wu CM, Li TM,
Fong YC and Tang CH: Ras activation mediates WISP-1-induced
increases in cell motility and matrix metalloproteinase expression
in human osteosarcoma. Cell Signal. 25:2812–2822. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tutar L, Tutar E, Özgür A and Tutar Y:
Therapeutic targeting of microRNAs in cancer: Future perspectives.
Drug Dev Res. 76:382–388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Leva G and Croce CM: miRNA profiling of
cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Hong F and Yu Z: Decreased
expression of microRNA-206 in breast cancer and its association
with disease characteristics and patient survival. J Int Med Res.
41:596–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo R, Wu Q, Liu F and Wang Y: Description
of the CD133+ subpopulation of the human ovarian cancer
cell line OVCAR3. Oncol Rep. 25:141–146. 2011.PubMed/NCBI
|
|
12
|
Yang Q, Zhang C, Huang B, Li H, Zhang R,
Huang Y and Wang J: Downregulation of microRNA-206 is a potent
prognostic marker for patients with gastric cancer. Eur J
Gastroenterol Hepatol. 25:953–957. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren J, Huang HJ, Gong Y, Yue S, Tang LM
and Cheng SY: MicroRNA-206 suppresses gastric cancer cell growth
and metastasis. Cell Biosci. 4:262014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vickers MM, Bar J, Gorn-Hondermann I,
Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ,
Maroun J, et al: Stage-dependent differential expression of
microRNAs in colorectal cancer: Potential role as markers of
metastatic disease. Clin Exp Metastasis. 29:123–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang T, Liu M, Wang C, Lin C, Sun Y and
Jin D: Down-regulation of MiR-206 promotes proliferation and
invasion of laryngeal cancer by regulating VEGF expression.
Anticancer Res. 31:3859–3863. 2011.PubMed/NCBI
|
|
16
|
Song G, Zhang Y and Wang L: MicroRNA-206
targets notch3, activates apoptosis, and inhibits tumor cell
migration and focus formation. J Biol Chem. 284:31921–31927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mataki H, Seki N, Chiyomaru T, Enokida H,
Goto Y, Kumamoto T, Machida K, Mizuno K, Nakagawa M and Inoue H:
Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR
oncogenic signaling in lung squamous cell carcinoma. Int J Oncol.
46:1039–1050. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yunqiao L, Vanke H, Jun X and Tangmeng G:
MicroRNA-206, down-regulated in hepatocellular carcinoma,
suppresses cell proliferation and promotes apoptosis.
Hepatogastroenterology. 61:1302–1307. 2014.PubMed/NCBI
|
|
19
|
Allen-Rhoades W, Kurenbekova L,
Satterfield L, Parikh N, Fuja D, Shuck RL, Rainusso N, Trucco M,
Barkauskas DA, Jo E, et al: Cross-species identification of a
plasma microRNA signature for detection, therapeutic monitoring,
and prognosis in osteosarcoma. Cancer Med. 4:977–988. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dennis GJ Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gene Ontology Consortium: The gene
ontology (GO) project in 2006. Nucleic Acids Res. 34:D322–D326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li S, Li Y, Wen Z, Kong F, Guan X and Liu
W: microRNA-206 overexpression inhibits cellular proliferation and
invasion of estrogen receptor α-positive ovarian cancer cells. Mol
Med Rep. 9:1703–1708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Ling C, Bai Y and Zhao J:
MicroRNA-206 is associated with invasion and metastasis of lung
cancer. Anat Rec (Hoboken). 294:88–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fritsche-Guenther R, Noske A, Ungethüm U,
Kuban RJ, Schlag PM, Tunn PU, Karle J, Krenn V, Dietel M and Sers
C: De novo expression of EphA2 in osteosarcoma modulates activation
of the mitogenic signalling pathway. Histopathology. 57:836–850.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu H, Liu X and Zhao J: Down-regulation of
miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem.
33:1547–1556. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Novello C, Pazzaglia L, Cingolani C, Conti
A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: miRNA
expression profile in human osteosarcoma: Role of miR-1 and
miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lian F, Cui Y, Zhou C, Gao K and Wu L:
Identification of a plasma four-microRNA panel as potential
noninvasive biomarker for osteosarcoma. PLoS One. 10:e1214992015.
View Article : Google Scholar
|
|
35
|
Georges S, Calleja LR, Jacques C, Lavaud
M, Moukengue B, Lecanda F, Quillard T, Gabriel MT, Cartron PF,
Baud'huin M, et al: Loss of miR-198 and −206 during primary tumor
progression enables metastatic dissemination in human osteosarcoma.
Oncotarget. 9:35726–35741. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan BL, Tong ZW, Wu L, Pan L, Li JE, Huang
YG, Li SD, Du SX and Li XD: Effects of MicroRNA-206 on osteosarcoma
cell proliferation, apoptosis, migration and invasion by targeting
ANXA2 through the AKT signaling pathway. Cell Physiol Biochem.
45:1410–1422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bao YP, Yi Y, Peng LL, Fang J, Liu KB, Li
WZ and Luo HS: Roles of microRNA-206 in osteosarcoma pathogenesis
and progression. Asian Pac J Cancer Prev. 14:3751–3755. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhan FB, Zhang XW, Feng SL, Cheng J, Zhang
Y, Li B, Xie LZ and Deng QR: MicroRNA-206 reduces osteosarcoma cell
malignancy in vitro by targeting the PAX3-MET axis. Yonsei Med J.
60:163–173. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM
and Zhang GZ: Biological functions of microRNAs: A review. J
Physiol Biochem. 67:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Y, Yang P and Wang XF:
Microenvironmental regulation of cancer metastasis by miRNAs.
Trends Cell Biol. 24:153–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Porter LA, Cukier IH and Lee JM: Nuclear
localization of cyclin B1 regulates DNA damage-induced apoptosis.
Blood. 101:1928–1933. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Warner SL, Bearss DJ, Han H and Von Hoff
DD: Targeting Aurora-2 kinase in cancer. Mol Cancer Ther.
2:589–595. 2003.PubMed/NCBI
|
|
44
|
Egloff AM, Vella LA and Finn OJ: Cyclin B1
and other cyclins as tumor antigens in immunosurveillance and
immunotherapy of cancer. Cancer Res. 66:6–9. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kao H, Marto JA, Hoffmann TK, Shabanowitz
J, Finkelstein SD, Whiteside TL, Hunt DF and Finn OJ:
Identification of cyclin B1 as a shared human epithelial
tumor-associated antigen recognized by T cells. J Exp Med.
194:1313–1323. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhong X, Guan X, Liu W and Zhang L:
Aberrant expression of NEK2 and its clinical significance in
non-small cell lung cancer. Oncol Lett. 8:1470–1476. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhong X, Guan X, Dong Q, Yang S, Liu W and
Zhang L: Examining Nek2 as a better proliferation marker in
non-small cell lung cancer prognosis. Tumour Biol. 35:7155–7162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou W, Yang Y, Xia J, Wang H, Salama ME,
Xiong W, Xu H, Shetty S, Chen T, Zeng Z, et al: NEK2 induces drug
resistance mainly through activation of efflux drug pumps and is
associated with poor prognosis in myeloma and other cancers. Cancer
Cell. 23:48–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Upregulation of NEK2 is associated with drug resistance in
ovarian cancer. Oncol Rep. 31:745–754. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee J and Gollahon L: Nek2-targeted ASO or
siRNA pretreatment enhances anticancer drug sensitivity in
triple-negative breast cancer cells. Int J Oncol. 42:839–847. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee J and Gollahon L: Mitotic
perturbations induced by Nek2 overexpression require interaction
with TRF1 in breast cancer cells. Cell Cycle. 12:3599–3614. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zeng YR, Han ZD, Wang C, Cai C, Huang YQ,
Luo HW, Liu ZZ, Zhuo YJ, Dai QS, Zhao HB, et al: Overexpression of
NIMA-related kinase 2 is associated with progression and poor
prognosis of prostate cancer. BMC Urol. 15:902015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Neal CP, Fry AM, Moreman C, McGregor A,
Garcea G, Berry DP and Manson MM: Overexpression of the Nek2 kinase
in colorectal cancer correlates with beta-catenin relocalization
and shortened cancer-specific survival. J Surg Oncol. 110:828–838.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Stricker TP, Henriksen KJ, Tonsgard JH,
Montag AG, Krausz TN and Pytel P: Expression profiling of 519
kinase genes in matched malignant peripheral nerve sheath
tumor/plexiform neurofibroma samples is discriminatory and
identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed
with transformation. Mod Pathol. 26:930–943. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ning Z, Wang A, Liang J, Liu J, Zhou T,
Yan Q and Wang Z: Abnormal expression of Nek2 in pancreatic ductal
adenocarcinoma: A novel marker for prognosis. Int J Clin Exp
Pathol. 7:2462–2469. 2014.PubMed/NCBI
|
|
56
|
Garbers C, Aparicio-Siegmund S and
Rose-John S: The IL-6/gp130/STAT3 signaling axis: Recent advances
towards specific inhibition. Curr Opin Immunol. 34:75–82. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hong DS, Angelo LS and Kurzrock R:
Interleukin-6 and its receptor in cancer: Implications for
translational therapeutics. Cancer. 110:1911–1928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yang Y, Wang W, Chang H, Han Z, Yu X and
Zhang T: Reciprocal regulation of miR-206 and IL-6/STAT3 pathway
mediates IL6-induced gefitinib resistance in EGFR-mutant lung
cancer cells. J Cell Mol Med. 23:7331–7341. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chang Q, Daly L and Bromberg J: The IL-6
feed-forward loop: A driver of tumorigenesis. Semin Immunol.
26:48–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Alvarez JV, Greulich H, Sellers WR,
Meyerson M and Frank DA: Signal transducer and activator of
transcription 3 is required for the oncogenic effects of
non-small-cell lung cancer-associated mutations of the epidermal
growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bournazou E and Bromberg J: Targeting the
tumor microenvironment: JAK-STAT3 signaling. JAKSTAT.
2:e238282013.PubMed/NCBI
|
|
62
|
Bid HK, Oswald D, Li C, London CA, Lin J
and Houghton PJ: Anti-angiogenic activity of a small molecule STAT3
inhibitor LLL12. PLoS One. 7:e355132012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Onimoe GI, Liu A, Lin L, Wei CC, Schwartz
EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, et al: Small
molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent
growth suppressive activity in osteosarcoma cells and tumor growth
in mice. Invest New Drugs. 30:916–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
